Spectrum Pharma Continues Study of Lymphoma (SPPI)

The Data Monitoring Committee has allowed Spectrum Pharmaceuticals SPPI to continue the study for belinostat in peripheral T-cell lymphoma, after the Committee performed a safety analysis.